Original Paper

Community Mental Health Journal

, Volume 50, Issue 1, pp 51-58

Open Access This content is freely available online to anyone, anywhere at any time.

Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia

  • Safiya AbouzaidAffiliated withHealth Economics and Outcomes Research, Novartis Pharmaceuticals Corporation
  • , Haijun TianAffiliated withHealth Economics and Outcomes Research, Novartis Pharmaceuticals Corporation
  • , Huanxue ZhouAffiliated withKMK Consulting Inc.
  • , Kristijan H. KahlerAffiliated withOutcomes Research Methods & Analytics, Novartis Pharmaceuticals Corporation
  • , Michelle HarrisAffiliated withHealth Economics and Outcomes Research, Novartis Pharmaceuticals Corporation
  • , Edward KimAffiliated withHealth Economics and Outcomes Research, Novartis Pharmaceuticals Corporation Email author 

Abstract

No studies have assessed the economic impact of extrapyramidal symptoms due to atypical antipsychotics in schizophrenia. To assess healthcare resource use and medical costs associated with extrapyramidal symptoms in patients with schizophrenia. A retrospective analysis of Marketscan® Medicaid Multi-State Database (2004–2009) was conducted. Patients with schizophrenia and newly initiated on an AAP were included. Patients with and without extrapyramidal symptoms were matched using propensity-score matching. Healthcare utilization and costs were assessed in the 12-month follow-up period using logistic and two-part (gamma) regression models. Of 4,621 patients, 583 (12.6 %) had extrapyramidal symptoms. Patients with extrapyramidal symptoms had significantly more schizophrenia-related and all-cause hospitalizations and schizophrenia-related emergency room visits, as well as significantly higher schizophrenia-specific and all-cause total healthcare, inpatient, and prescription drug costs compared to patients without extrapyramidal symptoms. Extrapyramidal symptoms in patients with schizophrenia is associated with increased healthcare resource utilization and higher medical costs.

Keywords

Extrapyramidal symptoms (EPS) Schizophrenia Healthcare utilization costs Direct medical costs